ISLET Act

The ISLET Act, introduced March 19, 2026, by Rep. Norman (R-SC-5), reclassifies human cadaveric islets as organs under the Public Health Service Act, removing them from FDA drug, biological product, and HCT/P definitions. The bill is in the earliest legislative stage — referred to the House Energy and Commerce Committee with only three actions on record (introduction and referral). No hearings, markups, or votes have occurred. The companion bill S3105 is also at a preliminary stage in the Senate HELP Committee. No funding is authorized or appropriated; the legislation is purely regulatory — it directs HHS to update existing regulations to reflect the new classification within one year of enactment. The affected entities are transplant centers (e.g., hospitals, organ procurement organizations) and the HHS regulatory apparatus. No publicly traded company is named or directly affected by this reclassification. Revenue impacts are zero for any energy companies ($ENPH, $XOM, $NEE, $CVX, $GEV, $FSLR, $COP, $DUK, $SO) in the provided financial data — this bill has no connection to energy production, generation, or consumption. No healthcare public companies (e.g., hospital chains, biotech, device makers) are named in the bill text or committee reports. The regulatory change is narrow — it affects how islet cell transplants are overseen, shifting authority from FDA drug/biological product pathways to the organ transplant framework under HRSA/OPTN. This is a procedural reclassification, not a market event. Remaining legislative path: committee consideration, potential House floor vote, Senate companion vote, conference if amended, then presidential signature. Given the single-subject, non-controversial nature of the bill (organic reclassification has bipartisan precedent), it may pass this congress, but the timeline is uncertain and impact on public equities is zero.